An Australian Capital Territory cohort study recorded 10‐year recurrence rates of 10.6% (luminal), 24.4% (HER2‐positive), and 26.4% (triple‐negative tumours) for breast cancer diagnosed during 2002–2015; DM accounted for 72% of recurrences.19 This evidence concerns the gene ERBB2 and breast cancer.